 BURLINGAME, Calif.--BUSINESS WIRE--Humanigen, Inc. Nasdaq: HGEN Humanigen, a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called cytokine storm, announced today it has entered into an arrangement with Clinigen Group plc Clinigen a global pharmaceutical Services and Products company, to implement a Managed Access Program for lenzilumab LenzMAPTM. LenzMAP will enable access to lenzilumab on a case-by-case basis for hospitali 